The International Vaccine Institute (IVI) said the Ministry of Health and Welfare had been named it to operate “2022 Global Bio-Intensive Training Courses,” a Korean government program.
IVI will provide workforce training in vaccine and biologics R&D and manufacturing for people from low- and middle-income countries (LMICs) and Korea.
The Global Bio-Intensive Training Courses is the Korean government’s first global training project in the biomanufacturing sector. The program aims to provide essential knowledge through an intensive short-term education to enhance students’ work capacity.
The IVI program includes biologics development and production, standard practice (GxP), onsite training, and consultation.
“IVI is thrilled to be selected as the operator of 2022 Global Bio-Intensive Training Courses,” said Jerome Kim, Director General of IVI. “We believe the selection is recognition by our host country of IVI’s robust capability and track record in training the global workforce in the vaccine and biologics industries.”
Headquartered in Korea, IVI will reinforce capacity building in vaccine and biologics development and manufacturing for countries worldwide, Kim went on to say.
He hoped to operate the training program successfully by achieving synergy with Korea’s advanced biomanufacturing industry.
The health and welfare ministry will support a 4.3 billion won fund for the new training program.
The program consists of two offline and one online course. Two offline courses will have 450 participants, including 150 from Korea. The online course will have no limit in the number of participants. Trainees will earn the necessary skills to develop and produce vaccines and biopharmaceuticals.
Also, IVI will provide customized onsite training and consultation to vaccine and biotech firms in LMICs to manufacture biopharmaceuticals in compliance with international regulatory standards.
“The core of a competitive bio-industry anywhere is a well-trained, adaptable workforce, innovative R&D, and efficient, high-quality manufacturing,” said Alice Lee, program lead of the 2022 Global Bio-Intensive Training Courses at IVI.
With partners in Korea and worldwide, IVI will provide quality training courses to biomanufacturing staff for LMICs interested in developing their biomanufacturing capacity and for Korea, she added.
IVI is the only international organization devoted exclusively to vaccine R&D for global public health.
Also, it is the only international organization to have developed and tech-transferred WHO prequalified vaccines to vaccine manufacturers in developing countries.